Submit Deal

Announced

20 Feb 2023

Completed

20 Feb 2023

Sofinnova, OMX and Vækstfonden led a $19.5m Series A round in Freya Biosciences.

Synopsis

Sofinnova, a venture capital firm, OMX, a venture capital firm, and Vækstfonden, Denmark's investment fund, led a $19.5m Series A round in Freya Biosciences, a clinical-stage company taking an innovative approach to women's health.

Principals

target

Freya Biosciences Aps

bidder

Sofinnova Partners

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (3)

colleen acosta

CEO at FREYA BIOSCIENCES APS

Manager

target

Deal

£ 16 M

Total Value

anders orjan jensen

Partner at Gorrissen Federspiel

Lawyer

target

Deals

£ 31.77 B

Total Value

andreas hertel

Counsel at Gorrissen Federspiel

Lawyer

target

Deals

£ 24.86 B

Total Value

Bidder Team (3)

antoine papiernik

Managing Partner at SOFINNOVA PARTNERS

Investor

bidder

Deals

£ 1.15 B

Total Value

rolf kjærgaard

CEO at VAEKSTFONDEN

Manager

bidder

Deal

£ 16 M

Total Value

daniel fero

Managing Director at OMX VENTURES

Manager

bidder

Deal

£ 16 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy